Breaking News

Gilead cancer drug trials hit with partial hold

Not rendering correctly? View this email as a web page here.

Biotech startup Septerna lands $100M to break new ground on an old drug target

By Frank Vinluan Thursday, January 27, 2022 7:00 AM

Septerna has science from a Nobel laureate and technology that finds new ways to drug GPCRs, well-validated receptors targeted by about one-third of FDA-approved medicines. According to CEO Jeff Finer, the startup is kicking off a second golden age of GPCR drug development.

Read more »

What does the federal 'No Surprises Act' mean in California?

By Bernard J. Wolfson, Kaiser Health News Wednesday, January 26, 2022 6:51 PM

Betty Chow, a Los Angeles resident, had a cervical disc replaced in August 2020 at […]

Read more »

Why CMS is giving chronic care management reimbursements a boost in 2022

By Tom Ferry Wednesday, January 26, 2022 6:36 PM

Six years in, the subtext of the scheduled reimbursements increase for 2022 is that CCM has proven to be an essential part of the care continuum, particularly in the wake of the Covid-19 pandemic, and has real value for patients, providers, and payers.

Read more »

Meet SkinIO, the startup that is bringing virtual specialty care to dermatology

By Michael Schroeder Wednesday, January 26, 2022 6:33 PM

As virtual specialty care options continue to expand and access remains limited to dermatologists, Smart Health Innovation Lab announced this week that the platform, which allows people to do a full-body skin screening using a smartphone app, has joined the healthcare technology accelerator.

Read more »

With $22M series A funding, Mantra Health launches long-term mental health program for college students

By Emma Bardin Wednesday, January 26, 2022 6:19 PM

Mantra Health, which provides digital mental health tools for university students, raised $22M in a Series A funding round to offer its evidence-based teletherapy and psychiatric services to patients with long term mental health issues.

Read more »

MedCity Pivot Podcast: A conversation with Stoke Therapeutics CMO regarding how to tackle Dravet Syndrome

By Arundhati Parmar Wednesday, January 26, 2022 4:37 PM

Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company's stock price decline isn't reflective of the true value of the therapy the company is hoping to commercialize.

Read more »

   

No comments